Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

ANDAs for minoxidil topical solution 5% submitted by Alpharma (75-518) and Copley Pharmaceuticals (75-619) were approved by FDA Nov. 17; Pharmacia's Rogaine Extra Strength for Men lost market exclusivity Nov. 14. Alpharma, which debuted its generic version of the hair regrowth treatment at the Private Label Manufacturers Association annual trade show in Chicago Nov. 13-14, began shipping the product Nov. 18. The 60 mL bottles will be sold in single-, double- and triple-packs and will retail for between $14.99 and $19.99 per bottle, the company says. Perrigo also plans to offer a generic version of minoxidil 5%, but was forced to push back the shipping date until April due to an unfavorable FDA inspection of its Allegan, Mich. facility (1"The Tan Sheet" Oct. 30, p. 13)

You may also be interested in...

Perrigo New Product Program, Quality Control Back On Track In FY 2002

Corrective actions taken in response to an unfavorable FDA inspection of Perrigo's Allegan, Mich. facility will preclude the planned November launch of minoxidil 5% and stall the company's pipeline, Perrigo told analysts in an Oct. 25 conference call.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts